Dexcel Pharma has co-led a $60m series A round for Immunai, which previously collected $20m in seed financing less than a year ago.

US-based immunotherapy developer Immunai received $60m in a series A round on Thursday co-led by speciality pharmaceutical firm Dexcel Pharma. Schusterman Family Investments, Duquesne Family Office and Catalio Capital Management co-led the round, which also attracted Viola Ventures and TLV Partners. Founded in 2018, Immunai‚Äôs technology combines high-resolution single-cell analytics with machine learning to uncover…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.